238 related articles for article (PubMed ID: 30895635)
21. Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.
Ramírez-Alcántara V; Montrose MH
Am J Physiol Gastrointest Liver Physiol; 2014 Jun; 306(11):G1002-10. PubMed ID: 24742986
[TBL] [Abstract][Full Text] [Related]
22. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis.
D'Incà R; Barollo M; Scarpa M; Grillo AR; Brun P; Vettorato MG; Castagliuolo I; Sturniolo GC
Dig Dis Sci; 2011 Apr; 56(4):1178-87. PubMed ID: 20737210
[TBL] [Abstract][Full Text] [Related]
23. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R
Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
Prenzler A; Yen L; Mittendorf T; von der Schulenburg JM
BMC Health Serv Res; 2011 Jul; 11():157. PubMed ID: 21729262
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of mucosal tissue associated microbiota in patients manifesting acute exacerbations and remission stage of ulcerative colitis.
Walujkar SA; Kumbhare SV; Marathe NP; Patangia DV; Lawate PS; Bharadwaj RS; Shouche YS
World J Microbiol Biotechnol; 2018 May; 34(6):76. PubMed ID: 29796862
[TBL] [Abstract][Full Text] [Related]
26. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
Stobaugh DJ; Deepak P; Thorpe M; Hannon B; Ehrenpreis ED
Inflamm Bowel Dis; 2013 Feb; 19(2):301-8. PubMed ID: 22644716
[TBL] [Abstract][Full Text] [Related]
27. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
28. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
29. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
30. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
[TBL] [Abstract][Full Text] [Related]
31. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
[TBL] [Abstract][Full Text] [Related]
32. A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).
Thorpe MP; Ehrenpreis ED; Putt KS; Hannon B
Aliment Pharmacol Ther; 2009 Jun; 29(11):1193-201. PubMed ID: 19222409
[TBL] [Abstract][Full Text] [Related]
33. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Sandborn WJ
J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
[TBL] [Abstract][Full Text] [Related]
34. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.
Matsuda R; Koide T; Tokoro C; Yamamoto T; Godai T; Morohashi T; Fujita Y; Takahashi D; Kawana I; Suzuki S; Umemura S
Inflamm Bowel Dis; 2009 Mar; 15(3):328-34. PubMed ID: 18942752
[TBL] [Abstract][Full Text] [Related]
35. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats.
Tozaki H; Odoriba T; Okada N; Fujita T; Terabe A; Suzuki T; Okabe S; Muranishi S; Yamamoto A
J Control Release; 2002 Jul; 82(1):51-61. PubMed ID: 12106976
[TBL] [Abstract][Full Text] [Related]
36. Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids.
Suárez J; Romero-Zerbo Y; Márquez L; Rivera P; Iglesias M; Bermúdez-Silva FJ; Andreu M; Rodríguez de Fonseca F
PLoS One; 2012; 7(5):e37729. PubMed ID: 22662201
[TBL] [Abstract][Full Text] [Related]
37. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
38. [Localization of salazopyrin in colonic mucosa patients with ulcerative colitis].
Kitano A; Tabata A; Obayashi M; Nakagawa M; Yasuda K; Fukushima R; Okabe H; Tomobuchi M; Nakamura S; Kashima K
Nihon Shokakibyo Gakkai Zasshi; 1993 Feb; 90(2):124-33. PubMed ID: 8096555
[TBL] [Abstract][Full Text] [Related]
39. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome.
McCoubrey LE; Seegobin N; Sangfuang N; Moens F; Duyvejonck H; Declerck E; Dierick A; Marzorati M; Basit AW
J Control Release; 2024 May; 369():630-641. PubMed ID: 38599548
[TBL] [Abstract][Full Text] [Related]
40. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
